|24 March 2016|

A pioneering new partnership between Regeneron Pharmaceuticals and Bayer will prioritise treatment for serious eye diseases.

The pair will jointly develop a combination therapy for patients with wet age-related macular degeneration or diabetic macular edema.

“Our collaboration with Bayer has been extremely successful to date, as we work together to combat vision loss around the world. Vision loss can often have devastating consequences to an individual’s quality of life,” said George D. Yancopoulos, Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “This new agreement reflects our shared commitment to being leaders in ophthalmology and to improving anatomical and visual outcomes for patients with retinal eye diseases.”

Dr Joerg Moeller, member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Development, added: “Bayer is strongly committed to further expanding its ophthalmology portfolio with innovative therapies for patients suffering from vision impairment.”